Spartalizumab (anti-PD-1)

Categories, Drug Discovery & Development, Immunooncology, Inhibitors and Compound Libraries, Inhibitory Antibodies

Spartalizumab (anti-PD-1)

Spartalizumab (anti-PD-1)

Add to cart

Categories: Categories Drug Discovery & Development Immunooncology Inhibitors and Compound Libraries Inhibitory Antibodies Tags: apoptosis Cell Cycle/Checkpoint Immunology/Inflammation inhibit Inhibitor PD-1/PD-L1 Spartalizumab (anti-PD-1)Spartalizumab (antiPD1) Brand: TargetMol

Description

[accordions]
[accordion title= “Chemical Properties“]

Molecular Weight

N/A

[/accordion]

[accordions]
[accordion title= “References and Literature“]

1. J. Vansteenkiste, et al. Journal of Thoracic Oncology. 2017, 12(11):suppl2, S2402.

[/accordion]

HOW CAN WE HELP YOU? Our specialists are to help you find the best product for your application. We will be happy to help you find the right product for the job.

Our Featured Solutions

Animal Models (Preclinical)
Bioprocess
Cell Culture
Cell Imaging & Analysis
Cells & Tissue Repository
Exosome
Growth Factors, Recombinant Proteins
Laboratory Instruments & Equipements
Microfluidics
Western Blotting and Protein Analysis

SERVICES

Customised Soft Hydrogels
Data Analytics
DNA Synthesis Services
GMP Industrial/Clinical Lab Set Up
Innovation Enabler
NTA Particle Analysis
Preclinical and Translational Research
Skin Testing

RESEARCH FIELD

Food & Alternative Protein
Aging & Neuroscience
Cell & Gene Therapy
Drug Discovery & Development
Skin & Personal Care

LEARNING CENTRE

Blog
Technical Content
Product Information

ATLANTIS BIOSCIENCE PTE LTD

362 Upper Paya Lebar Rd, #07-15,
Singapore 534963

+65-8608 0974

[email protected]

LINE info

© 2015-2023 Atlantis Bioscience Pte Ltd. All rights reserved. Co Reg No: 201539516N